shop talk - nursingcenter
TRANSCRIPT
5O
nco
logy Tim
es • Novem
ber 25, 2014 • oncolog
y-times.com
The following members of the oncology community have been newly elected to the Institute of Medicine:• José Baselga, MD, PhD,
Physician-in-Chief and Chief Medical Officer of Memorial Sloan Kettering Cancer Center;• Carol R. Bradford, MD, the
Charles J. Krause Collegiate Professor and Chair of the Department of Otolaryngology—Head and Neck Surgery at the University of Michigan Health System;• Lewis C. Cantley, PhD, Director
of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College/New York-Presbyterian Hospital;• Arturo Casadevall, MD, PhD,
Chairman of the Department of Microbiology and Immunology at Albert Einstein College of Medicine;• E. Antonio Chiocca, MD,
PhD, Neurosurgeon-in-Chief and Co-director of the Institute for the Neurosciences at Brigham and Women’s/Faulkner Hospital, Surgical Director of the Center for Neuro-oncology at Dana-Farber Cancer Institute, and the Harvey W. Cushing Professor of Neurosurgery at Harvard Medical School;• James E. Crowe Jr., MD, Director
of Vanderbilt Vaccine Center and the Ann Scott Carell Chair Professor in the
Departments of Pediatrics, Pathology, Microbiology, and Immunology at Vanderbilt University Medical Center;• Joseph M. DeSimone, PhD,
Chancellor’s Eminent Professor of Chemistry and the William R. Kenan Jr. Distinguished Professor of Chemistry and Pharmacology at the University of North Carolina and North Carolina State University;• James Economou, MD, PhD, Vice
Chancellor for Research and Beaumont Professor of Surgery at UCLA;• Todd R. Golub, MD, Howard
Hughes Medical Institute Investigator, Chief Scientific Officer at Broad Institute of Harvard and Massachusetts Institute of Technology, and the Charles A. Dana Investigator at Dana-Farber Cancer Institute;• Paul A. Khavari, MD, PhD,
Professor and Chairman of the Department of Dermatology at Stanford University;• Sara Kenkare-Mitra, PhD, Senior
Vice President of Development Sciences at Genentech Research and Early Development at Hoffmann La-Roche;• Brian K. Kobilka, MD, Professor
of Molecular and Cellular Physiology at Stanford University School of Medicine;• Guillermina Lozano, PhD,
Professor and Chair of the Department of Genetics at the University of Texas MD Anderson Cancer Center;• David R. Piwnica-Worms,
MD, PhD, Professor and Chair of the
Department of Cancer Systems Imaging and Deputy Head of the Division of Imaging at the University of Texas MD Anderson Cancer Center;• Randy Wayne Schekman, PhD,
Howard Hughes Medical Institute Investigator and Professor of Cell and Developmental Biology at the University of California, Berkeley;• Margaret A. Shipp, MD, Chief of
the Division of Hematology Neoplasia at Dana-Farber Cancer Institute; • Bruce M. Spiegelman, PhD, the
Stanley J. Korsmeyer Professor of Cell Biology and Medicine at Dana-Farber Cancer Institute and Harvard Medical School; and• Dan Theodorescu, MD, PhD,
the Paul A. Bunn Cancer Research Chair. Professor of Surgery and Pharmacology, and Director of the University of Colorado Comprehensive Cancer Center.
Zhu Chen, MD, PhD, Vice Chairman of the 12th Standing Committee of the National People’s Congress, has re-ceived the 2014 American Association for Cancer Research Award for Distinguished Public Service and Global Impact in Cancer Research in Biomedical Science, given at AACR’s in-augural meeting in China. He also deliv-ered the opening plenary lecture during the meeting, “New Horizons in Cancer Research: Harnessing Breakthroughs—Targeting Cures.”
“Dr. Chen epitomizes the scientific work of this vast nation, and it is our honor to recognize him for his achieve-ments. As the minister of health in China, he has been, and continues to be in his current important role, a vision-ary leader and proponent for cancer re-search, biomedical science, and improved public health,” AACR President Carlos L. Arteaga, MD, said in a news release.
Chen has previously served as China’s Minister of Health (2007-2013) and Director of the Chinese National Human Genome Center. His own re-search focused on the concept of com-bination targeted therapies for cancer and provided the first successful model in the treatment of acute promyelocytic leukemia with all-trans retinoic acid and arsenic trioxide, which turned the previously fatal hematologic malig-nancy into a largely curable disease. Lili Yang, PhD, Assistant Professor of Microbiology, Immunology, and Molecular Genetics at UCLA Jonsson C o m p r e h e n s i v e Cancer Center, has received a National Institutes of Health Direc tor ’s New Innovator Award of $2.3 million for her research develop-ing new ways to genetically program
Shop Talk
LILI YANG, PHD
continued on page 6
Editorial BoardChairman: Robert C. Young, MD Emeritus Chancellor, Fox Chase Cancer Center
Clinical Advisory Editor for Hematology/Oncology: John C. Byrd, MD, the D. Warren Brown Chair of Leukemia Research; Professor of Medicine, Medicinal Chemistry, and Veterinary Biosciences; Director, Division of Hematology, The Ohio State University.
Clinical Advisory Editor for Oncology: Ramaswamy Govindan, MD, Co-Director, Section of Medical Oncology, Professor of Medicine, Washington University School of Medicine, Alvin J Siteman Cancer Center
Joseph S. Bailes, MD, Partner, Texas Oncology; Chairman, Cancer Prevention and Research Institute of Texas Foundation
Paul A. Bunn Jr., MD, Exec. Director, International Assoc. for the Study of Lung Cancer; James Dudley Endowed Professor of Lung Cancer Research, Univ. of Colorado
Michael A. Caligiuri, MD Director, Ohio State University Comprehensive Cancer Center; CEO, The James Cancer Hospital and Solove Institute
Harold P. Freeman, MD, Founder, President and CEO, Harold P. Freeman Patient Navigation Institute
Joyce Hendershott, MSW, ACSW, LISW-S Associate Director, Patient Education Department, The Ohio State University James Cancer Hospital & Solove Research Institute
Richard T. Hoppe, MD, Professor, Radiation Oncology; Member, Stanford Cancer Institute, Stanford University
Robert J. Mayer, MD, Faculty Vice President for Academic Affairs, Dana-Farber Cancer Institute; Faculty Associate Dean for Admissions and Stephen B. Kay Family Professor of Medicine, Harvard Medical School
Frank L. Meyskens, Jr., MD, Daniel C. Aldrich, Jr. Endowed Chair and Professor of Medicine, Biological Chemistry, and Public Health; Vice Dean, School of Medicine; Director Emeritus, Chao Family Comprehensive Cancer Center, University of California, Irvine
Joseph V. Simone, MD, President, Simone Consulting
Ellen Stovall, Senior Health Policy Advisor, National Coalition for Cancer Survivorship
Paul A. Volberding, MD Director, AIDS Research Institute, University of California, San Francisco; Director of Research, UCSF Global Health Sciences
Carolyn Weaver RN, MSN, AOCN, AHN-BC Oncology Clinical Nurse Educator, Quintiles
Norman Wolmark, MD Chairman and Principal Investigator, National Surgical Adjuvant Breast and Bowel Project; Chairman, Dept. of Human Genetics, Allegheny General Hospital Cancer Center, Pittsburgh
EDITOR: Serena Stockwell
ASSOCIATE EDITOR: Sarah diGiulio
PRODUCTION MANAGER: Stacy Drossner
DESKTOP MANAGER: Peter Castro
PRODUCTION, iPad App: Sarah Lemore
MANAGER OF CIRCULATION: Deborah Benward
COLUMNISTS/BLOGGERS: Lola Butcher; Wendy Harpham, MD; Joseph V. Simone, MD; George W. Sledge, Jr., MD; Andrew Turrisi, MD
CONTRIBUTING WRITERS: Mary Brophy Marcus, Robert H. Carlson, Peggy Eastman, Mark Fuerst, Peter Goodwin, Heather Lindsey, Kurt Samson, Ed Susman
DIRECTOR, PUBLISHING: Theresa M. Steltzer
VICE PRESIDENT, NURSING, HEALTH & WELLNESS PUBLISHING: Jennifer E. Brogan
VICE PRESIDENT, PUBLISHING: Jayne Marks
PRESIDENT AND CEO, WOLTERSKLUWER HEALTH MEDICAL RESEARCH: Cathy Wolfe
VICE PRESIDENT, GLOBAL SALES: Gareth Williams
VICE PRESIDENT, ADVERTISING SALES: Fabien Savenay
SALES DIRECTOR, LWW JOURNALS: Ray Lender
SENIOR NATIONAL ACCOUNT MANAGER: Ben Harkinson Wolters Kluwer Health, Lippincott Williams & Wilkins 100 River Ridge Drive, Suite 207 Norwood, MA 02062; 781-440-4854 fax: 646-607-4253, [email protected]
CLASSIFIED ADVERTISING: Mike Rusch, 215-521-8404, fax 215-689-2453; [email protected]
REPRINTS: Bridget Quinn, 215-521-8807; fax:215-405-3812 [email protected]
Vol. 36, No. 22
11/25/14
Editorial/PublishingofficEs: 333seventhave.,19thfl.,newYork,nY10001;
[email protected],oncology-times.com
6O
nco
logy
Tim
es •
Nov
emb
er 2
5, 2
014
• on
colo
gy-
times
.com
human blood stem cells to attack tumor cells. The award is designed specifically to support unusually creative new in-vestigators with highly innovative re-search ideas.
Yang’s previous research has fo-cused on invariant natural killer T cells (iNKT), which have been found to have the capacity to mount an immedi-ate and powerful response to diseases when activated. Her current work will develop a new way to model how to ge-netically program human blood stem cells to become iNKT cells.
“The potential for iNKT T cell re-ceptor-based gene therapy is very ex-citing because it is very different from conventional T cell receptor-based gene therapy, which can only target specific types of tumor and a certain group of patients,” Yang said in a news release. “The kind of iNKT T cell receptor gene therapy we are investigating could have universal application, treating many types of cancer and a large group of patients no matter what types of tumor they have. It holds tremendous promise for the future.”
Nicholas J. Petrelli, MD, FACS, the Bank of America Endowed Medical Director of Christiana Care’s Helen F. Graham Cancer Center and Research Institute in Newark, Delaware, has received the As s o c i a t i on o f Community Cancer Centers’ 2014 Clinical Research Award, honoring his leadership initiatives promoting
and advocating for oncology clinical research.
Petrelli led the development of the Clinical Oncology Care Program at the Helen F. Graham Cancer Center, which has served as a National Cancer Institute Community Cancer Center Program site and has achieved an accrual rate of 24 percent in NCI-sponsored clini-cal trials. In August the Center earned a five-year $8.2 million grant from the NCI’s Community Oncology Research Program.
Petrelli also spearheaded the de-velopment of a Tissue Procurement Center with over 4,000 specimens, catalogued through the NCI’s Cancer Bioinformatics Grid, which led to $4.6 million in funding for participation in the Cancer Genome Atlas Project. And he developed the first Delaware state-wide High Risk Family Cancer Registry, consisting of 2,500 families with more than 200,000 individuals.
William G. Kaelin, Jr., MD, Professor in the Department of Medicine and Associate Director for Basic Science, both at the Dana-Farber Cancer Institute at Harvard Medical School, has received the 2014 Steven C. Beering Award for Outstanding Achievement in Biomedical Science, presented annually by Indiana University School of Medicine.
Kaelin’s work focuses on under-standing how mutations affecting tumor-suppressing genes cause can-cer in order to develop new antican-cer therapies. He received the award in October on the IU-Purdue University
Indianapolis Campus and presented the lecture, “The Von Hippel-Lindau Tumor Suppressor: Insights into Oxygen Sensing and Cancer.”
Leonidas Platanias, MD, PhD, has been appointed Director of Robert H. Lurie C o m p r e h e n s i v e C a n ce r Ce n te r of Northwestern University. He has served in the posi-tion in interim since January. Platanias will oversee both the clinical operations in the Lurie Cancer Center and grow-ing basic science research programs, including programs to translate basic and clinical research into personalized medicine.
“Leon has already contributed greatly to the Lurie Cancer Center, through both his leadership and his sci-entific achievements,” Eric G. Neilson, MD, Vice President for Medical Affairs and the Lewis Landsberg Dean at Northwestern University Feinberg School of Medicine, said in a news re-lease. “As permanent director, he will continue in that vein, driving the cen-ter’s expansion and maintaining its reputation as a premiere venue for re-search, clinical care and collaboration.”
Platanias init ia l ly joined Northwestern University Feinberg School of Medicine in 2002 as Lurie Cancer Center’s first Deputy Director and the Jesse, Sara, Andrew, Abigail, Benjamin, and Elizabeth Lurie Professor of Oncology. He has also previously served as Chief of the Division of Hematology/Oncology at the University of Illinois at Chicago. His research has focused on molecular biology and bio-
chemistry, particularly on signaling pathways in cancer cells and cytokines.
In other Lurie Cancer Center news, Francis J. Giles, MB, MD, FRCPI, FRCPath, has been appointed Deputy Director. He will oversee Northwestern Medicine’s clinical research cancer pro-grams and develop-mental therapeutics initiatives.
“Frank has already made major con-tributions to the Lurie Cancer Center,” Platanias said in a news release. “He brings exceptional expertise and ex-perience in clinical and translational research and has a major interest in education and mentorship of faculty in developmental therapeutics and per-sonalized medicine.”
Giles previously served as the Lurie Cancer Center’s Associate Director for Translational Research and Developmental Therapeutics, and has been Director of Northwestern Medicine Developmental Therapeutics Institute since 2013. He is a Fellow of the Royal College of Physicians of Ireland, the Royal College of Pathologists (UK), and the European Academy of Cancer Sciences.
Linda Malkas, PhD, has been named Deputy Director of Basic Research at City of Hope C o m p r e h e n s i v e Cancer Center. In the role, she will chair the Cancer Center
NICHOLAS J. PETRELLI, MD, FACS
FRANCIS J. GILES, MB, MD, FRCPI, FRCPATH
WILLIAM G. KAELIN, JR., MD
SHOP TALKContinued from page 5
continued on page 3
LEONIDAS PLATANIAS, MD, PHD
LINDA MALKAS, PHD
33 ’Turning the Tide’ Recommendations on
Patient-centered Care
24Large Study Documents
Many Psychological Problems in Cancer Patients
46 Long-term Catheter
Use: Greater Infection Risk in Older Patients
29 Searching for Reasons Patients Refuse Treatment
42 NSCLC: Lobectomy Best for Older Patients, But Alternatives Gaining Ground
43 Next-Gen Sequencing Challenges in Cancer Care
79 Follicular Lymphoma: For Low-Tumor Burden Disease, Rituximab Re-treatment Favored Over Maintenance
90 Consortium Probes Risk Factors for Newly ID’d Lymphoma Subtypes
92 Breast Cancer: Novel Vaccine Given Adjuvantly Decreases Recurrence in High-risk Patients
94 Profiles in Oncology Social Media: Stanley Winokur, MD, OncologyGuru.com
103 Allogeneic SCT Produces Long-Term Remission; GVT Effect Exists in Myeloma
106 Combinations Extend PFS in Advanced Melanoma
INSIDE . . . 64 Strength after
Breast Cancer: Empowering Survivors to Reduce Lymphedema Risk
65The Changing
Face & Gaining Acceptance of Palliative Surgery
74The Ins & Outs
of Promoting Your Research on Social Media
Onco
logy Tim
es • 11/25/147
Leadership Committee, helping guide scientific efforts and fostering collabo-ration among laboratory researchers. She also will oversee faculty mentor-ing, internal research funding, and the development of multi-investigator re-search projects under the Cancer Center Support Grant as well as the research core facilities. She assumes the role after an interim position as Associate Director of Basic Sciences.
Malkas is also a member of the National Cancer Institute Parent Committee. She first joined City of Hope in 2011 from Indiana University, where she was Founder and Director of the Indiana Center for Breast Cancer Research. Along with her new duties, she will continue as Associate Chair and the M.T. and B.A. Ahmadinia Professor in the Department of Molecular and Cellular Biology at City of Hope.
In other City of Hope news, Matthew Ruchin, MBA, joins as Associate Director. He was most recently at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center as Interim Associate Director for Administration.
Richard C. Zellars, MD , has been named Professor and Chair of Radiation Oncology at Indiana University School of Medicine, where he will start in January. He was previously Associate Professor of Radiation Oncology at Johns Hopkins University School of Medicine and Assistant Director of Clinical Trial Accrual at Sidney Kimmel Comprehensive Cancer Center.
His research has focused on the safety and efficacy of radiation for the treatment of breast cancer, as well as on health care disparities in African-American women who typically have more severe radiation toxicities. While at Johns Hopkins, Zellars founded the Cancer in the Under-Privileged, Indigent or Disadvantaged Summer Fellowship, which exposes first-year medical stu-dents who have a demonstrated interest in serving disadvantaged populations to the specialty of oncology.
The Centers for Disease Control and Prevention’s Division of Cancer Prevention and Control has awarded $1.7 million over five years to Johns Hopkins Kimmel Cancer Center’s Breast Cancer Program to fund educational programs and support other efforts to increase awareness for young women diagnosed with breast cancer.
“We have recognized the urgent need for a specialty clinic for young women
diagnosed with breast cancer, as their needs are unique and must be addressed in a dedicated and coordinated way,” Ve re d S te a r n s , MD, Professor of Oncology and Co-director of the Breast Cancer Program, said in a news release.
“The funds provided by the CDC will allow us to extend our pilot ef-forts to reach a larger proportion of young women in more comprehensive
ways, providing not only treatment of their disease, but also care for them as individuals—whether they are going to school, building careers, or raising families.”
The U.S. Food and Drug Administration has awarded 15 grants totaling more than $19 million through its Orphan Products Grants Program to promote the development of products for rare diseases. Grant recipients from the on-cology community are:• Mitesh Borad, MD, of Mayo
Clinic Arizona, for “Phase I Study of VSV-hIFN-B for the Treatment of
Hepatocellular Carcinoma” (approxi-mately $600,000 over three years);• Andrew Brenner, MD, PhD, of the
University of Texas Health Center San Antonio, for “Phase II Study of TH-302 for the Treatment of Glioblastoma” (ap-proximately $1.6 million over four years);• Donald Durden, MD, PhD, of
the University of California San Diego, for “Phase II Study of Poly-ICLC for the Treatment of Pediatric Low Grade Gliomas” ($1.6 million over four years);• Alfred Lane, MD, of Stanford
University, for “Phase II Study of Sildenafil for the Treatment of
SHOP TALKContinued from page 6
VERED STEARNS, MD
MATTHEW RUCHIN, MBA
RICHARD C. ZELLARS, MD
continued on page 8
Onco
logy
Tim
es •
11/
25/1
4 8
Lymphatic Malformations” (approxi-mately $1.6 million over four years);• Dung Le, MD, of Johns Hopkins
University, for “Phase II Study of Folfirinox followed by Ipilimumab/GVAX for the Treatment of Pancreatic Cancer” ($1.6 million over four years); and• Jana Portnow, MD, of City of
Hope Beckman Research Institute, for “Phase I study of Neural Stem Cell & 5-FC/Leucovorin for the Treatment of Recurrent High Grade Gliomas” ($600,000 over three years).
The Van Andel Research Institute-Stand Up To Cancer Epigenetics Dream Team has received a commitment of $7.5 million from Van Andel Research Institute (VARI) to continue its work led by co-leaders Peter A. Jones, PhD, DSc, Research Director and Chief Scientific Officer of VARI and Stephen Baylin, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.
“We are extremely excited to build on the foundations already laid by the Epigenetics Dream Team by mov-ing promising thera-pies into clinical trials,” Jones said in a news release. “Epigenetics provides untold op-portunities to expand our knowledge of the mechanisms underlying cancer and to develop new treatments that posi-tively affect people’s lives.”
The team’s work so far has involved clinical trials investigating the response
of patients with lung cancer to epi-genetic therapy alone, or as a way to sensitize patients to subsequent che-motherapy. VARI’s support over the next three years will allow the team to move forward with more extensive clinical trials in other cancer types, as well as test additional epigenetic ther-apy strategies.
The St. Baldrick’s Foundation has awarded $501,600 in childhood cancer research grants to the Johns Hopkins Kimmel Cancer Center’s Division of Pediatric Oncology
SHOP TALKContinued from page 7
continued on page 9
PETER A. JONES, PHD, DSC
STEPHEN BAYLIN, MD
Onco
logy Tim
es • 11/25/149
to suppor t the wor k of these physician-scientists:• Eric Raabe,
PhD, MD, received the “Heroes for Hannah” grant, a $230,000 award to support an-other two years of his project focused on medulloblastoma;• Christopher Gamper, MD, PhD,
received $115,000 to support his St.
Baldrick’s Scholar award for his work on immunotherapy strategies and de-creasing the risk of late effects by re-ducing the need for chemotherapy and radiation;• Colleen
Annesley, MD, re-ceived the Tap Cancer Out St. Baldrick’s Fellow award, $97,500, to support an additional year of her research on spe-cific mutations in acute myeloid leuke-mia; and
• Jeffrey Lukish, MD, received a $59,100 Supportive Research Grant to support his work on preserving fertility in pediatric cancer patients.
G r a c e S a u z i e r, RN, BSN, CBCN, Nurse Navigator at Carolinas HealthCare System’s Lev ine Cancer Institute, has received the 2014 Onco lo g y Nurse Navigator Life Changer Award for the commitment
and compassion she demonstrates in her role. She has served at Carolinas HealthCare System for more than eight years working with patients with breast cancer.
“Caring for breast cancer patients, and helping them work through the various concerns and questions that arise throughout their course of treat-ment is my passion,” Sauzier said in a news release. “I am honored that these patients appreciate, and feel benefited by my services, which are demonstrated by our entire team of nurse navigators, on a daily basis.”
SHOP TALKContinued from page 8
continued on page 10
CHRISTOPHER GAMPER, MD, PHD
ERIC RAABE, PHD, MD
GRACE SAUZIER, RN, BSN, CBCN
Onco
logy
Tim
es •
11/
25/1
4 10
The annual award is sponsored by Health Monitor in collaboration with the Academy of Nurse Navigators.
METAvivor Research and Support Inc., a non-profit organization dedicated to Stage IV metastatic breast cancer, has granted four awards totaling $247,000 in scientific research grants. The recipi-ents are:• Balamurugan Kuppusamy,
PhD, of the National Cancer
Institute, for his work, “Inflammatory Breast Cancer: Role of the CEBPD-FBXW7 Signaling Pathway”;• Wi l l i a m P.
Schiemann, PhD, of Case Western Reserve University, for his work, “Implement-ing a Forward Genetic Screen to Identify Novel Proto-Oncogenes Operant in Overcoming Metastatic Dormancy”;
• S w a r n a l i Acharyya, PhD, of the Institute for Cancer Genetics at Columbia University, for her work, “Reactivating anti-tumor granu-locytic cells to pro-voke immune attack against breast cancer metastasis”; and• Eran Andrechek, PhD, of
Michigan State University, for his work, “Identification of driver mutations that regulate metastasis.”
The National Cancer Institute has awarded a one-year, $150,000 supplemental grant to Roswell Park Cancer Institute as part of an effort to increase the number of ado-lescents receiving the HPV vaccine, the three-dose vaccine that protects against infection of some high-risk strains of human papillo-mavirus responsible for most cases of
SHOP TALKContinued from page 9
continued on page 11
WILLIAM P. SCHIEMANN, PHD
SWARNALI ACHARYYA, PHD
ERAN ANDRECHEK, PHD
Onco
logy Tim
es • 11/25/1411
cervical and anal cancers, as well as many genital and head and neck cancers.
The primary goals of this project include completing an environmental scan to identify and establish partner-ships with relevant stakeholders such as local and regional health care plans, hospitals, pediatric practices and other medical groups that provide care to ad-olescents and teens, agencies, immuni-zation coalitions, urgent-care centers, school nurses, Native American tribes,
minority health coalitions, and col-leges and universities, a news release notes. This effort will yield a com-pendium of information summariz-ing local/regional data, programs and resources focused on HPV vaccination and cataloging the chal-lenges to HPV vacci-nation specific to the Western New York region.
The effort will be run by Frances Harfouche, MSW,
Evaluation Coordinator, and Christy Widman, Cancer Control Coordinator, both within Roswell Park’s Division of Cancer Prevention and Population
Sciences; and overseen by Martin C. Mahoney, MD, PhD, a primary care physician and researcher in RPCI’s Population Sciences Program. O
T
SHOP TALKContinued from page 10
FRANCES HARFOUCHE, MSW
CHRISTY WIDMAN
MARTIN C. MAHONEY, MD, PHD
Share Your News!
Send information and photos for this column to